Liraglutide: What the Research Actually Shows
The original once-daily GLP-1 receptor agonist, with a large, placebo-controlled cardiovascular outcomes trial that reached statistical superiority, genuinely strong evidence, even though two separate head-to-head randomized trials show it produces meaningfully less weight loss and glycemic improvement than the newer once-weekly drugs it's now most often compared against.
A Once-Daily GLP-1 Receptor Agonist, the First of Its Engineered Class
Liraglutide is a synthetic analogue of human glucagon-like peptide-1 (GLP-1), the same gut-derived incretin hormone semaglutide and tirzepatide are built around: it stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and acts on appetite-regulating centers in the hypothalamus to reduce food intake. Its engineering, developed years before semaglutide's, established the basic playbook every GLP-1 drug since has followed: a single palmitic acid chain is attached through a glutamic acid linker to lysine at position 26, while an Arg34Lys substitution allows that fatty acid to be attached at a specific, controlled site during manufacturing. The resulting reversible binding to circulating albumin partially protects the molecule from rapid degradation by the enzyme DPP-4 and slows its absorption, extending its elimination half-life to roughly 13 hours, versus the one-to-two-minute half-life of native GLP-1. That's enough for once-daily dosing, but far short of the roughly one-week half-life semaglutide's longer fatty-diacid chain and additional stabilizing substitutions would later achieve. It is FDA-approved under different brand names for different indications, Victoza for type 2 diabetes (approved 2010) and Saxenda for chronic weight management (approved 2014, at a higher 3.0 mg dose than Victoza's), and this guide covers the compound's evidence base broadly rather than brand-specific dosing.
Evidence Summary
A Strong Cardiovascular Outcomes Trial, and a Clear Loss on Weight Loss to the Drugs That Followed It
Discovery and Mechanism: The Original Fatty-Acid-Acylation Strategy
Knudsen LB, Lau J. "The Discovery and Development of Liraglutide and Semaglutide." Frontiers in Endocrinology. 2019;10:155. doi: 10.3389/fendo.2019.00155. This review documents liraglutide's engineering: a palmitate (C16) fatty acid attached through a γGlu linker to lysine 26, with an Arg34Lys substitution enabling site-specific acylation during a semi-recombinant manufacturing process. The reversible albumin binding this produces gives partial protection from DPP-4 degradation and delayed subcutaneous absorption, extending the elimination half-life to approximately 13 hours and enabling once-daily dosing, the same fatty-acid-acylation strategy that semaglutide and tirzepatide would later extend with longer fatty-diacid chains and additional stabilizing substitutions to reach roughly week-long half-lives.
Medicinal Chemistry / Pharmacokinetic Review · Endpoint: Receptor Binding, Albumin-Binding Chemistry, and Half-Life, Mechanistic and Engineering Basis, Not a Clinical OutcomeWeight Loss: The SCALE Obesity and Prediabetes Randomized Controlled Trial
Pi-Sunyer X, Astrup A, Fujioka K, et al. "A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management." New England Journal of Medicine. 2015;373(1):11-22. doi: 10.1056/NEJMoa1411892. PMID: 26132939. This randomized, double-blind, placebo-controlled trial enrolled 3,731 adults with obesity or overweight (without diabetes) and randomized them 2:1 to once-daily subcutaneous liraglutide 3.0 mg or placebo, both alongside lifestyle intervention, for 56 weeks. Liraglutide produced a mean body weight change of -8.0% versus -2.6% with placebo (p<0.001), and 63.2% of the liraglutide group achieved at least 5% weight loss versus 27.1% with placebo. Gastrointestinal adverse events were common with liraglutide, nausea in 40.2% (versus 14.7% with placebo), diarrhea in 20.9% (versus 9.3%), and constipation in 20.0% (versus 8.7%).
Human RCT (n=3,731), Randomized and Double-Blind · Endpoint: Percent Body Weight Change at 56 Weeks, Large-Scale, Placebo-ControlledCardiovascular Outcomes: The LEADER Trial
Marso SP, Daniels GH, Brown-Frandsen K, et al. "Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes." New England Journal of Medicine. 2016;375:311-322. doi: 10.1056/NEJMoa1603827. PMID: 27295427. This large randomized, double-blind, placebo-controlled trial enrolled 9,340 patients with type 2 diabetes at high cardiovascular risk and followed them for a median of 3.8 years. The primary composite outcome, cardiovascular death, nonfatal heart attack, or nonfatal stroke, occurred in 13.0% of the liraglutide group versus 14.9% with placebo (hazard ratio 0.87, 95% CI 0.78-0.97, p=0.01 for superiority). Cardiovascular death specifically was reduced (hazard ratio 0.78, 95% CI 0.66-0.93, p=0.007), as was death from any cause (hazard ratio 0.85, 95% CI 0.74-0.97, p=0.02). This is genuine hard-outcome cardiovascular evidence from a placebo-controlled trial that reached statistical superiority, the same evidentiary tier as semaglutide's SELECT trial, not the noninferiority-only result seen with tirzepatide's active-comparator cardiovascular trial.
Human RCT (n=9,340), Randomized, Double-Blind, Placebo-Controlled · Endpoint: Composite Cardiovascular Events Over a Median 3.8 Years, Hard Clinical Outcomes, Reached Statistical SuperiorityWhat the Weight Loss Is Made Of: A Small Body Composition Study
Basolo A, Paolucci G, Piaggi P, et al. "Effects of 6-month treatment with the GLP-1 receptor agonist liraglutide on 24-hour energy metabolism and body composition in adults with obesity." Journal of Endocrinological Investigation. 2025;48(11):2735-2745. doi: 10.1007/s40618-025-02717-y. This prospective study followed 11 adults with obesity (8 female, mean age 49) through 6 months of clinically titrated liraglutide treatment. Total weight fell by 10.5 kg (p<0.001), made up of an 8.7 kg reduction in fat mass (p<0.001) and a 1.7 kg reduction in lean soft tissue (p=0.02), meaning roughly 83% of weight lost was fat mass and about 16% was lean tissue, a favorable ratio. This is a real finding, but from a single-center study of 11 patients, a much smaller and less definitive evidence base than semaglutide's 140-patient conference-presented analysis or tirzepatide's 160-patient full peer-reviewed sub-study, and should be weighted accordingly.
Small Prospective Study, DXA Body Composition (n=11), Full Peer-Reviewed Publication · Endpoint: Fat Mass and Lean Mass Change at 6 Months, Real but Substantially Underpowered Relative to the Other Two Drugs' Body Composition EvidenceLiraglutide Against the Newer Drugs: Two Genuine Head-to-Head Trials
Rubino DM, Greenway FL, Khalid U, et al. "Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial." JAMA. 2022;327(2):138-150. doi: 10.1001/jama.2021.23619. PMID: 35015037. And: Capehorn MS, Catarig AM, Furberg JK, et al. "Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10)." Diabetes & Metabolism. 2020;46(2):100-109. doi: 10.1016/j.diabet.2019.101117. These are genuine, randomized, head-to-head active-comparator trials, not cross-trial extrapolation. In STEP 8 (n=338, 68 weeks), semaglutide produced significantly greater weight loss than liraglutide, -15.8% versus -6.4% (p<0.001), with fewer discontinuations overall (13.5% versus 27.6%) despite similar overall rates of GI adverse events (84.1% versus 82.7%). In SUSTAIN 10 (n=577, 30 weeks, type 2 diabetes), semaglutide produced a significantly larger HbA1c reduction (1.7 percentage points versus 1.0, p<0.0001) and greater weight loss (5.8 kg versus 1.9 kg), with four times as many patients reaching an HbA1c below 7.0% (80% versus 46%). Both trials point the same direction: liraglutide is measurably outperformed by semaglutide on both weight loss and glycemic control, in trials designed specifically to make that comparison directly rather than across separate placebo-controlled studies.
Two Human RCTs, Head-to-Head Active-Comparator Design (n=338 and n=577) · Endpoint: Percent Body Weight Change and HbA1c Reduction, Direct Randomized Comparisons Against Semaglutide, Not Cross-Trial ExtrapolationA Real Gallbladder and Biliary Disease Signal
Nauck MA, Muus Ghorbani ML, Kreiner E, Saevereid HA, Buse JB; LEADER Publication Committee. "Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial." Diabetes Care. 2019;42(10):1912-1920. doi: 10.2337/dc19-0415. PMID: 31399438. This dedicated sub-analysis of the LEADER trial population found a statistically significant increase in acute gallbladder or biliary disease with liraglutide versus placebo, 141 of 4,668 patients versus 88 of 4,672 (hazard ratio 1.60, 95% CI 1.23-2.09, p<0.001), a consistent pattern across uncomplicated gallstones, complicated gallstones, cholecystitis, and biliary obstruction. This is a better-powered, more directly demonstrated gallbladder signal than the simple adverse-event-rate comparison available for tirzepatide, and belongs in any honest accounting of liraglutide's risk profile.
Pre-Specified Sub-Analysis of a Large RCT (n=9,340) · Endpoint: Acute Gallbladder and Biliary Disease Events, Statistically Significant, Well-Powered Safety FindingWhat the Research Doesn't Yet Show
Liraglutide's cardiovascular outcomes evidence is genuinely strong, but its weight-loss and glycemic effects are measurably weaker than the once-weekly drugs that followed it, and that gap is demonstrated in direct head-to-head trials, not inferred across separate studies. As with semaglutide and tirzepatide, the FDA's boxed warning states plainly that liraglutide causes thyroid C-cell tumors in rodents at clinically relevant exposures, and that "human relevance of liraglutide-induced rodent thyroid C-cell tumors has not been determined," a real regulatory caution built on animal data, not a demonstrated human cancer risk; it is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2, the same restriction that applies to semaglutide and tirzepatide. A dedicated LEADER sub-analysis found a statistically significant, well-powered increase in acute gallbladder and biliary disease with liraglutide, a real risk worth weighing, and a stronger signal than what's currently documented for tirzepatide. Body composition data is real but comes from a single small study of 11 patients, a much thinner evidence base than what exists for semaglutide or tirzepatide, so the favorable fat-to-lean ratio it found should be read as suggestive rather than definitive. And while weight regain after stopping treatment is a well-documented expectation across the GLP-1 drug class generally, a liraglutide-specific published trial extension with a directly demonstrated regain percentage, the way semaglutide's STEP 1 extension provides, was not found, so that point is stated here as a general class expectation rather than a liraglutide-specific finding.
Liraglutide is FDA-approved under specific brand names for specific indications, Victoza for type 2 diabetes and Saxenda for chronic weight management, at specific doses and formulations. It is not an unregulated or investigational compound in the way most other peptides on this site are.
How This Fits the Cellular Medicine Framework
Liraglutide sits at the same cell-signaling tier as semaglutide, a hormone-mimetic peptide engineered to activate the GLP-1 receptor, and its history is a useful illustration of how a framework built around a single well-characterized signal can be refined without being replaced. The receptor target, the downstream biology, and the basic engineering strategy, fatty-acid acylation for albumin binding, are all the same ideas semaglutide and tirzepatide later extended with longer fatty-diacid chains, additional stabilizing substitutions, and, in tirzepatide's case, a second receptor target entirely. Liraglutide's continued relevance despite being outperformed on weight loss is also instructive: a strong, placebo-controlled, superiority-grade cardiovascular outcomes trial is its own independent piece of evidence, not something that gets erased by a newer drug producing more weight loss in an unrelated trial. Each outcome, weight, glycemic control, cardiovascular events, has to be demonstrated on its own terms, and liraglutide's record shows a compound that can be simultaneously the weakest of three drugs on one outcome and hold real, superiority-grade evidence on another.
References
- Knudsen LB, Lau J. The Discovery and Development of Liraglutide and Semaglutide. Front Endocrinol (Lausanne). 2019;10:155. doi:10.3389/fendo.2019.00155
- Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11-22. doi:10.1056/NEJMoa1411892 · PMID: 26132939
- Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375:311-322. doi:10.1056/NEJMoa1603827 · PMID: 27295427
- Basolo A, Paolucci G, Piaggi P, et al. Effects of 6-month treatment with the GLP-1 receptor agonist liraglutide on 24-hour energy metabolism and body composition in adults with obesity. J Endocrinol Invest. 2025;48(11):2735-2745. doi:10.1007/s40618-025-02717-y
- Rubino DM, Greenway FL, Khalid U, et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022;327(2):138-150. doi:10.1001/jama.2021.23619 · PMID: 35015037
- Capehorn MS, Catarig AM, Furberg JK, et al. Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes Metab. 2020;46(2):100-109. doi:10.1016/j.diabet.2019.101117
- Nauck MA, Muus Ghorbani ML, Kreiner E, Saevereid HA, Buse JB; LEADER Publication Committee. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care. 2019;42(10):1912-1920. doi:10.2337/dc19-0415 · PMID: 31399438
- U.S. Food and Drug Administration. SAXENDA (liraglutide) injection, prescribing information (boxed warning: thyroid C-cell tumors). accessdata.fda.gov
Explore the Rest of the Knowledge Center
Hormones, Women's Health, Men's Health, Peptides, and Metabolic Health, five practical categories, one shared framework underneath all of them.